EU cross-border healthcare directive should give industry a bigger part in HTA decisions, says EUCOPE
This article was originally published in Scrip
Executive Summary
The European Union cross-border healthcare directive should include a provision to ensure that the pharmaceutical industry has greater involvement in health technology assessment decisions before they are finalised, says Dr Alexander Natz, secretary general of EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs.